Harbour BioMed Unveils 2025 Financial Results and Future Plans for Global Growth #China #Shanghai #biopharmaceuticals #Harbour_BioMed #antibody_therapeutics
0
0
0
0
Hashtag
#Harbour_BioMed
Advertisement · 728 × 90
Harbour BioMed Announces Phase I Results for HBM9378, A Novel TSLP-Targeting Antibody #China #Chengdu #HBM9378 #Harbour_BioMed #TSLP
0
0
0
0
Harbour BioMed Welcomes Dr. Jenny Xie as New Chief Scientific Officer for Immunology #China #Shanghai #Harbour_BioMed #Immunology #Jenny_Xie
1
0
0
0
NMPA Approves SKB575/HBM7575 for Treating Atopic Dermatitis in China #China #Chengdu #Kelun-Biotech #Harbour_BioMed #SKB575
0
0
0
0
Harbour BioMed and Kelun-Biotech's Breakthrough in Atopic Dermatitis Treatment with IND Approval #China #Kelun-Biotech #Rotterdam #Harbour_BioMed #HBM7575
0
0
0
0
Harbour BioMed Reports Significant Profit Growth Expectations for 2025 #United_States #Cambridge #Harbour_BioMed #antibody_therapeutics #Profit_Alert
0
0
0
0
Harbour BioMed Strengthens Ties with Spruce Biosciences Through Stock Acquisition #None #Harbour_BioMed #Spruce_Biosciences #HBM_Alpha_Therapeutics
0
0
0
0
Harbour BioMed and Lannacheng's Alliance Aiming for Radionuclide Drug Conjugate Innovations #China #Shanghai #radiopharmaceuticals #Harbour_BioMed #Lannacheng
1
0
0
0
Harbour BioMed and Bristol Myers Squibb Forge Strategic Partnership for Advanced Antibody Development #China #Shanghai #Bristol_Myers_Squibb #Harbour_BioMed #antibody_therapeutics
1
0
0
0
Harbour BioMed Expands Collaboration with AstraZeneca for Innovative Oncology Therapies #None #AstraZeneca #Cambridge,_Massachusetts #biotherapeutics #Harbour_BioMed
0
0
0
0
Harbour BioMed and Evinova China Forge AI Partnership for Drug Development #China #Shanghai #AI_Collaboration #Harbour_BioMed #Evinova
1
0
0
0
Harbour BioMed Introduces Innovative AI Model for Antibody Discovery #United_States #Generative_AI #Cambridge #Harbour_BioMed #HCAb_Model
0
0
0
0
Harbour BioMed Reports Promising Phase II Study Outcomes of HBM4003 with Tislelizumab for mCRC Treatment #None #Harbour_BioMed #Tislelizumab #HBM4003
0
0
0
0
Harbour BioMed Unveils Impressive Growth in 2025 Interim Results with Focus on Innovation #China #Shanghai #Harbour_BioMed #Immunology #Antibody_Technology
0
0
0
0
Harbour BioMed Welcomes Yajie Li as New Chief Medical Officer #China #Shanghai #Biopharmaceutical #Harbour_BioMed #Yajie_Li
0
0
0
0
Harbour BioMed to Showcase HBM4003 and Tislelizumab Trial Results at ESMO 2025 #None #Harbour_BioMed #Tislelizumab #HBM4003
0
0
0
0
Harbour BioMed Predicts Significant Profit Growth for First Half of 2025 #None #AstraZeneca #Harbour_BioMed #HBICE
0
0
0
0
Harbour BioMed's Groundbreaking Phase 2 Trial of HBM9378/WIN378 for Asthma #None #HBM9378 #Harbour_BioMed #Anti-TSLP
0
0
0
0
Harbour BioMed Teams Up with Otsuka for Bispecific T-Cell Engager Innovation #China #Shanghai #Harbour_BioMed #Otsuka #Bispecific_T-Cell_Engagers
0
0
0
0
Harbour BioMed Secures Patent Validity and Advances Legal Battle Against Biocytogen in China #China #Shanghai #Harbour_BioMed #Biocytogen #HCAb_Patent
0
0
0
0
New Leadership at Harbour BioMed: Youchen Chen Takes on CFO Role to Enhance Financial Strategy #China #Shanghai #CFO #Harbour_BioMed #Youchen_Chen
0
0
0
0
Harbour BioMed's 2024 Financial Results Show Robust Growth Amid Challenges #None #biopharmaceuticals #Harbour_BioMed #HCMab_Technology
0
0
0
0
Harbour BioMed and AstraZeneca Forge Alliance for Next-Gen Therapeutic Antibodies #China #Beijing #AstraZeneca #Harbour_BioMed #Antibody_Technology
0
0
0
0
Harbour BioMed Launches Élancé Therapeutics for Innovative Obesity Solutions #None #bispecific_antibody #Harbour_BioMed #Élancé_Therapeutics
0
0
0
0
Harbour BioMed Welcomes Dr. Ian Y. Liu as Global Head of Legal to Propel Legal Strategies #United_States #Cambridge #Harbour_BioMed #antibody_therapeutics #Dr._Ian_Y._Liu
0
0
0
0
Michael D. Patten Joins Harbour BioMed as Chief Strategy Officer to Drive Global Growth #China #Shanghai #Harbour_BioMed #Michael_Patten #strategy_officer
0
0
0
0
Strategic Alliance Formed Between Harbour BioMed and Insilico Medicine to Propel AI-Driven Antibody Innovations #None #Insilico_Medicine #Harbour_BioMed #Antibody_Discovery
0
0
0
0
Harbour BioMed Reports Significant Business Growth and Updates for Stakeholders #China #Shanghai #biotechnology #Harbour_BioMed #antibody_therapeutics
0
0
0
0
Harbour BioMed's Groundbreaking Approval for New COPD Treatment Marks a Major Step Forward #China #Shanghai #Harbour_BioMed #HBM9378/SKB378 #COPD
0
0
0
0
Harbour BioMed Partners with Windward Bio to Advance HBM9378/SKB378 for Immunological Disease Treatment #None #HBM9378 #Windward_Bio #Harbour_BioMed
0
0
0
0